22nd Century Group Inc (NYSEAMERICAN:XXII) was the target of a large growth in short interest during the month of March. As of March 29th, there was short interest totalling 23,372,484 shares, a growth of 0.7% from the March 15th total of 23,217,501 shares. Based on an average daily volume of 1,611,057 shares, the short-interest ratio is presently 14.5 days. Approximately 20.6% of the company’s shares are short sold.

Shares of XXII traded down $0.06 on Tuesday, reaching $1.82. The stock had a trading volume of 2,082,000 shares, compared to its average volume of 1,862,099. 22nd Century Group has a 12-month low of $1.58 and a 12-month high of $3.29.

22nd Century Group (NYSEAMERICAN:XXII) last posted its quarterly earnings data on Wednesday, March 6th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter. The business had revenue of $7.14 million during the quarter.

Several large investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC grew its position in 22nd Century Group by 13.5% during the 4th quarter. Geode Capital Management LLC now owns 1,166,476 shares of the biotechnology company’s stock valued at $2,904,000 after purchasing an additional 139,131 shares during the last quarter. Advisory Services Network LLC bought a new stake in 22nd Century Group in the 4th quarter worth about $142,000. Amalgamated Bank purchased a new position in 22nd Century Group in the 4th quarter worth about $44,000. HRT Financial LLC purchased a new position in 22nd Century Group in the 4th quarter worth about $33,000. Finally, Cetera Advisors LLC lifted its stake in 22nd Century Group by 16.9% during the 4th quarter. Cetera Advisors LLC now owns 27,615 shares of the biotechnology company’s stock valued at $68,000 after acquiring an additional 4,000 shares during the period.

A number of research firms recently issued reports on XXII. TheStreet downgraded shares of 22nd Century Group from a “c-” rating to a “d+” rating in a research note on Friday, March 29th. Chardan Capital reaffirmed a “buy” rating and set a $11.50 price objective on shares of 22nd Century Group in a research report on Friday, March 15th.

TRADEMARK VIOLATION WARNING: “22nd Century Group Inc (XXII) Sees Significant Increase in Short Interest” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://www.watchlistnews.com/22nd-century-group-inc-xxii-sees-significant-increase-in-short-interest/2951402.html.

About 22nd Century Group

22nd Century Group, Inc, a plant biotechnology company, provides technology that allows increasing or decreasing the level of nicotine and other nicotinic alkaloids in tobacco plants, and cannabinoids in hemp/cannabis plants through genetic engineering and plant breeding. The company offers premium cigarettes under the RED SUN and MAGIC brands; and SPECTRUM research cigarettes for use in independent clinical studies.

Further Reading: What is a balanced fund?

Receive News & Ratings for 22nd Century Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 22nd Century Group and related companies with MarketBeat.com's FREE daily email newsletter.